𝘒𝘙𝘈𝘚-Targeted Therapies in Gynecologic Oncology

Activity Overview

Over the past decade, oncology has begun to leverage a rapidly maturing effort to target the KRAS protein in KRAS-altered cancers. This has led to the introduction of targeted therapies with the potential to offer unprecedented benefit to patients. Still, these agents differ greatly in their mechanisms of action, relevant alterations, and adverse event profiles.

In this module, expert faculty discuss the use of RAS/MAPK inhibitors in the setting of RAS-altered gynecologic malignancies. In particular, the speakers will address patient selection, expectations regarding efficacy, and the management of adverse events associated with novel targeted therapies for these patients.

Target Audience

This activity is directed toward medical oncologists, gynecologic oncologists, radiation oncologists, pathologists, and other health care professionals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate efficacy and safety of current and emerging KRAS/RAS-targeted therapies in solid tumors
• Incorporate clinical trial data on KRAS/RAS-targeted therapies into treatment selection considerations for individual patients with solid tumors
• Apply appropriate AE mitigation and management strategies for patients with solid tumors receiving KRAS/RAS-targeted therapies

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners before the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.